Dr. Mark Joseph Messing, MD

Dr. Messing practices at Texas Oncology PA in Bedford, Texas.

Dr. Messing's NPI, 1932141033, was assigned on June 12, 2006. Dr. Messing graduated from Emory School of Medicine in 1984. Dr. Messing's Texas license number on file is H7467.

Dr. Messing's primary practice is Texas Oncology PA, at 1609 Hospital Pkwy, Bedford, TX 76022 in Tarrant County. The practice phone is (972) 997-8000.

Dr. Messing's primary practice is Texas Oncology PA in Bedford, Texas. Dr. Messing is also affiliated with Texas Health Harris Methodist Hospital Hurst-Euless-Bedford. The medical group on file is Texas Oncology. Dmand AI also links Dr. Messing to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Messing practices, 4 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Messing's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Messing is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Messing's licenses on file in 3 states: Texas, Georgia and Alabama.

Dmand AI lists hysterectomy among the conditions Dr. Messing treats.

CMS data shows 1,127 Medicare services from Dr. Messing across 12 procedure codes in 2024, for 130 Medicare patients. Medicare paid $51,782 for them. Every service was in an office.

CMS counts 130 Medicare patients who saw Dr. Messing in 2024. The largest group is 65 to 74, with 65 patients. 75% of them have high cholesterol, and 73% have high blood pressure. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Messing's median patient age at 63, with 99% women.

In 2024, Dr. Messing wrote 309 Medicare Part D claims for 77 patients. 88% of them were for generic drugs. CMS names the drug for 221 of them, across 10 drugs with 11 or more claims each, at $19,556 in total drug cost. In 2023, CMS named 233 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Messing for performance year 2024, reported through an alternative payment model (APM). Dr. Messing accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Messing as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 17 papers to Dr. Messing, published from 2009 to 2024. The most frequent topics are Ovarian Neoplasms, Adenocarcinoma and Antibodies, Monoclonal, Humanized. Dr. Messing has published most often in Gynecol Oncol. Dr. Messing's most frequent co-authors are Carol Aghajanian, MD, Marcia S. Brose, MD and Allen L. Cohn, MD.

Dmand AI links Dr. Messing to 5 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Ovarian Neoplasms, Triple Negative Breast Neoplasms and Uterine Cervical Neoplasms.

CMS Open Payments shows 27 general payments to Dr. Messing from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 48% of the total. Intuitive Surgical, Inc. paid the most, $1,311.

Dmand AI lists 4 awards for Dr. Messing, most recently ACS Fellow in 2012.

Dr. Messing graduated from Emory School of Medicine in 1984. Dr. Messing is a member of AOA, AAGL, American College of Obstetricians and Gynecologists, ACS, AMA and TMA.

Dr. Messing is in network with 22 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.